Navigation Links
Study by Pittsburgh researchers identifies possible vaccine target for chlamydia
Date:9/12/2007

Scientists at Childrens Hospital of Pittsburgh of UPMC have identified a potential target for the development of a vaccine against Chlamydia trachomatis, the most prevalent sexually transmitted bacterial infection in the world.

The researchers, led by Toni Darville, MD, chief of the Division of Pediatric Infectious Diseases at Childrens, identified a plasmid-deficient strain of Chlamydia that, when investigated in an animal model of genital tract infection, failed to cause disease. Plasmids are small molecules of DNA.

Results of their study are published in the Sept. 15 issue of the Journal of Immunology.

This finding represents a major step forward in our work to eventually develop a vaccine against chlamydial disease, said Dr. Darville, senior author of the study and also a professor of pediatrics and microbiology/immunology at the University of Pittsburgh School of Medicine. If we can identify plasmid-deficient derivatives of the C. trachomatis strains that infect humans, they would have the potential to serve as a vaccine against this disease.

Dr. Darville is considered one of the worlds foremost researchers of Chlamydia trachomatis, a bacterium which is the most frequently reported cause of sexually transmitted disease in the United States. Because symptoms are usually mild or absent, it can damage a womans reproductive organs and cause irreversible damage, including infertility, before a woman ever recognizes a problem.

In this study, a plasmid-deficient strain derived from Chlamydia muridarum was introduced to mice. The mice became infected but did not develop the trademark signs of chlamydial disease, particularly damage to the oviduct, the tube that carries eggs from the ovaries, according to Catherine M. OConnell, PhD, a researcher in Dr. Darvilles laboratory and first author of the study.

Not only did the mice not develop oviduct scarring after infection with the plasmid-deficient strain, we als
'/>"/>

Contact: Marc Lukasiak
marc.lukasiak@chp.edu
412-692-7919
Children's Hospital of Pittsburgh
Source:Eurekalert

Page: 1 2

Related biology news :

1. Bioartificial kidney under study at MCG
2. Novel Asthma Study Shows Multiple Genetic Input Required; Single-gene Solution Shot Down
3. W.M. Keck Foundation funds study of friendly microbes
4. Yellowstone microbes fueled by hydrogen, according to U. of Colorado study
5. Emory Study Tests Bone Marrow Stem Cells to Improve Circulation in Legs
6. UCLA Study Shows One-Third of Drug Ads in Medical Journals Do Not Contain References Supporting Medical Claims
7. Study Demonstrates Gene Expression Microarrays are Comparable and Reproducible
8. Study Links Ebola Outbreaks To Animal Carcasses
9. Genome-wide mouse study yields link to human leukemia
10. Breakthrough Microarray-based Technology for the Study of Cancer
11. NYU Study Reveals How Brains Immune System Fights Viral Encephalitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... 2014 Nxt-ID, Inc. (OTCQB: NXTD), a biometric ... announced today that its shares of common stock and ... in its proposed underwritten public offering of common stock ... Nasdaq Capital Market, subject to closing of its proposed ... and will trade under the symbol "NXTD" and "NXTDW," ...
(Date:8/21/2014)... a previously unknown process for harvesting energy and producing ... Penn State University scientist has discovered. The discovery lays ... growth, harvesting energy from the Sun, and understanding dense ... other lakes worldwide. A paper describing the discovery will ... of the journal Science on 21 August ...
(Date:8/21/2014)... easy to ignore, but they are the ultimate source ... Humans are increasingly dependent on algae, too, to suck ... it to the bottom of the ocean. Now, by ... researchers have evidence showing that viruses infecting those algae ... even when all else stays essentially the same, and ...
Breaking Biology News(10 mins):Nxt-ID Approved for NASDAQ Capital Market Listing 2Nxt-ID Approved for NASDAQ Capital Market Listing 3Hot-spring bacteria reveal ability to use far-red light for photosynthesis 2Hot-spring bacteria reveal ability to use far-red light for photosynthesis 3Viruses take down massive algal blooms, with big implications for climate 2
... (hNoV), also known as the winter vomiting bug, is one ... virus is highly contagious, causing vomiting and diarrhea, and the ... cure; sufferers have to let the virus run its course ... is frequently associated with outbreaks of hNoV but it remains ...
... The human skin is home to countless microorganisms that we ... Our invisible passengers known as the skin microbiome - ... immune system, protecting us from pathogens, and mediating skin disorders. ... is transmitted between players in a contact sport, using roller ...
... in French . Researchers at the University ... discovered a new mechanism that allows some cells in our body ... by Roman soldiers depicted in the Asterix series. Collective cell migration ... but it is also used by cancerous cells to disseminate efficiently ...
Cached Biology News:What impact does a day of roller derby have on our skin microbiome? 2Asterix's Roman foes -- Researchers have a better idea of how cancer cells move and grow 2
(Date:8/21/2014)... Wednesday of last week RENU 28, the world's first and ... for purchase in Australia and New Zealand, and the response ... is, if you think about the definition of aging, it's ... within your body. If you think about the definition of ... What RENU 28 does is it works with these tiny ...
(Date:8/20/2014)... Neurotrope, Inc. (OTCQB: NTRP) today announced ... provide an update on Company activities. Access information:Date:Tuesday, ... 505-4369 (U.S. and Canada) or (719) 325-2315 Conference ... under "Investor Relations"The teleconference replay will be available ... 2014 at (888) 203-1112 (U.S. and ...
(Date:8/20/2014)... Toronto, Canada (PRWEB) August 20, 2014 ... wisdom that E&L studies should be performed late in ... system is known. But current regulatory trends suggest that, ... are on the rise. In recent years, multiple drug ... E&L packages or address specific questions during phase I/II. ...
(Date:8/19/2014)... August 20, 2014 One of ... medicine is an inadequate vascular supply. Nutrient and ... decellularized tissues is critical for successful regeneration and ... to mitigate deficiencies in vascularization and promote angiogenesis ... bioactivity, optimizing scaffold design and architecture, and enhancing ...
Breaking Biology Technology:RENU 28 Skin Care Now Available in Australia and New Zealand 2Neurotrope To Host Conference Call 2Are Extractable and Leachables going Phase-Appropriate? New Webinar Hosted by Xtalks 2Vascularization in Tissue Engineering Highlighted at 12th New Jersey Symposium on Biomaterials Science 2
... Helix BioPharma Corp. (TSX, FSE: "HBP") announced ... in Germany to initiate its planned Phase II ... with low-grade cervical lesions.The clinical study was designed, ... on the absorption and elimination profile of Topical ...
... Percent of Outstanding Indevus Shares Have Been Accepted ... Pharmaceuticals (Nasdaq: ENDP ) announced today ... time, on March 13, 2009, approximately 71,008,964 shares ... were validly tendered and accepted for purchase in ...
... PortfolioNEW YORK, March 16 Samtheo Biopharma LLC ... subsidiary, Lyndor Biosciences LLC, with Moffitt Cancer Center, ... that selectively inhibits the activation of all three ... pathway has been found to play an important ...
Cached Biology Technology:Helix BioPharma Receives Approval to Initiate Phase II Pharmacokinetic Clinical Study of Topical Interferon Alpha-2b in Patients with Low-Grade Cervical Lesions 2Helix BioPharma Receives Approval to Initiate Phase II Pharmacokinetic Clinical Study of Topical Interferon Alpha-2b in Patients with Low-Grade Cervical Lesions 3Helix BioPharma Receives Approval to Initiate Phase II Pharmacokinetic Clinical Study of Topical Interferon Alpha-2b in Patients with Low-Grade Cervical Lesions 4Helix BioPharma Receives Approval to Initiate Phase II Pharmacokinetic Clinical Study of Topical Interferon Alpha-2b in Patients with Low-Grade Cervical Lesions 5Endo Pharmaceuticals Extends Subsequent Offering Period for Indevus Shares Until 5:00 pm EDT on Wednesday, March 18, 2009 2Endo Pharmaceuticals Extends Subsequent Offering Period for Indevus Shares Until 5:00 pm EDT on Wednesday, March 18, 2009 3Samtheo Announces License Agreement with Moffitt Cancer Center for Exclusive Rights to Novel Akt Inhibitor 2Samtheo Announces License Agreement with Moffitt Cancer Center for Exclusive Rights to Novel Akt Inhibitor 3
Mouse monoclonal [1C6/2] to Rad17 ( Abpromise for all tested applications). entrezGeneID: 5884 SwissProtID: Q9UPF5...
... Spin Columns contain a proprietary high-performance desalting ... desalting and protein-recovery characteristics compared to other ... as 25 g/ml of protein can be ... 95% retention of salts and other small ...
Rabbit polyclonal to VPAC2 ( Abpromise for all tested applications). entrezGeneID: 7434 SwissProtID: P41587...
... Immunogen: ... acids 22-37 SGHKSEEKREKMKRTL Antigen ... G-protein signalling; Antigen Subfamily: ... G-protein signalling Recommended Storage: ...
Biology Products: